menu
    • menu
    [{"orgOrder":0,"company":"BTG Specialty Pharmaceuticals","sponsor":"Serb","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SERB Completes Acquisition of BTG Specialty Pharmaceuticals to Create a Global Leader in Critical Care Medicines","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"March 2021","year":"2021","type":"Acquisition","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"BTG Specialty Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"BTG Specialty Pharmaceuticals \/ SERB","highestDevelopmentStatusID":"12","companyTruncated":"BTG Specialty Pharmaceuticals \/ SERB"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Higher Dosage of Naloxone Nasal Spray to Treat Opioid Overdose","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","year":"2021","type":"Not Applicable","leadProduct":"Naloxone Hydrochloride","moa":"Mu Opoid receptor","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Hikma Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Hikma Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Hikma Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Ohara Pharmaceutical","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze\u00ae in The US","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2021","year":"2021","type":"Not Applicable","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Ohara Pharmaceutical","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Ohara Pharmaceutical \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Serb","sponsor":"BTG Specialty Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SERB Receives Positive CHMP Opinion for Voraxaze\u00ae (Glucarpidase) as Rescue Therapy for High Dose Methotrexate Toxicity","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"November 2021","year":"2021","type":"Not Applicable","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Serb","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Serb \/ BTG Specialty Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Serb \/ BTG Specialty Pharmaceuticals"},{"orgOrder":0,"company":"Rising Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection, an Important Antidote Treatment to Address Lead Poisoning","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Edetate Calcium Disodium","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Rising Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Rising Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Rising Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Meridian Medical Technologies","sponsor":"ASPR","pharmaFlowCategory":"D","amount":"$9.9 million","upfrontCash":"Undisclosed","newsHeadline":"Meridian Medical Technologies, Kindeva Drug Delivery\u2019s Global Health Security Division, Awarded Contract to Supply DuoDote\u00ae","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"November 2023","year":"2023","type":"Agreement","leadProduct":"Atropine","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Meridian Medical Technologies","amount2":0.01,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Meridian Medical Technologies \/ ASPR","highestDevelopmentStatusID":"12","companyTruncated":"Meridian Medical Technologies \/ ASPR"},{"orgOrder":0,"company":"Moksha8 Pharmaceuticals","sponsor":"SERB Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Agreement with SERB Pharmaceuticals to Bring Voraxaze\u00ae (glucarpidase) to Latin America","therapeuticArea":"Pharmacology\/Toxicology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"March 2024","year":"2024","type":"Agreement","leadProduct":"Glucarpidase","moa":"","url1":"","url2":"","graph1":"Pharmacology\/Toxicology","graph2":"Approved","graph3":"Moksha8 Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Pharmacology\/Toxicology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Toxicology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Moksha8 Pharmaceuticals \/ SERB Pharmaceuticals"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            IPEX Indonesia
                            Not Confirmed

                            Novartis Pharmaceuticals Corporation

                            Switzerland arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Deferoxamine Mesylate

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved

                            Sponsor : Mitem Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            MITEM Pharma Acquires DESFERAL® Rights Backed by TECHLIFE CAPITAL, MACSF

                            Details : Mitem acquires Desfera (deferoxamine mesylate) products from Novartis. It is indicated for treating iron overload, and forex, following blood transfusions necessary for treating beta-thalassemia.

                            Brand Name : Desfera

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 25, 2024

                            Lead Product(s) : Deferoxamine Mesylate

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved

                            Sponsor : Mitem Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed

                            Moksha8 Pharmaceuticals

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved

                            Sponsor : SERB Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Agreement with SERB Pharmaceuticals to Bring Voraxaze...

                            Details : M8 will register, market and commercialize SERB's supportive oncology product Voraxaze (glucarpidase), a carboxypeptidase that reduces toxic plasma methotrexate concentration, in Latin America.

                            Brand Name : Voraxaze

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 20, 2024

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved

                            Sponsor : SERB Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Meridian Medical Technologies

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed

                            Meridian Medical Technologies

                            U.S.A arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved

                            Sponsor : ASPR

                            Deal Size : $9.9 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Meridian Medical Technologies, Kindeva Drug Delivery’s Global Health Security Division, Awarded Contract to ...

                            Details : Under the agreement, Meridian will supply DuoDote to the Administration for Strategic Preparedness and Response within the United States. DuoDote® is an FDA-approved dual-chamber autoinjector (atropine and pralidoxime chloride) chemical nerve agent anti...

                            Brand Name : DuoDote

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 14, 2023

                            Lead Product(s) : Atropine,Pralidoxime Chloride

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved

                            Sponsor : ASPR

                            Deal Size : $9.9 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rising Pharmaceuticals

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed

                            Rising Pharmaceuticals

                            Country arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Edetate Calcium Disodium

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Rising Pharmaceuticals Launches Edetate Calcium Disodium Injection, an Important Antidote Treatment to Address...

                            Details : Edetate calcium disodium for injection is a prescription medicine, used for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults.

                            Brand Name : Edetate Calcium Disodium-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 10, 2023

                            Lead Product(s) : Edetate Calcium Disodium

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Serb

                            Belgium arrow
                            IPEX Indonesia
                            Not Confirmed

                            Serb

                            Belgium arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            SERB Receives Positive CHMP Opinion for Voraxaze® (Glucarpidase) as Rescue Therapy for High Dose Methotrexate...

                            Details : Company recieved positive opinion of CHMP of Voraxaze® (glucarpidase) based on clinical data and real world experience. Voraxaze reduces toxic plasma methotrexate concentration in adults and children may quickly lower MTX levels and avoid further system...

                            Brand Name : Voraxaze

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 25, 2021

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ohara Pharmaceutical

                            Japan arrow
                            IPEX Indonesia
                            Not Confirmed

                            Ohara Pharmaceutical

                            Japan arrow
                            IPEX Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Approved

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BTG Specialty Pharmaceuticals Advances Global Regulatory Program for Glucarpidase, Sold as Voraxaze® in The U...

                            Details : Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance due to impaired renal function.

                            Brand Name : Megludase

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 28, 2021

                            Lead Product(s) : Glucarpidase

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Approved

                            Sponsor : BTG Specialty Pharmaceuticals

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hikma Pharmaceuticals

                            United Kingdom arrow
                            IPEX Indonesia
                            Not Confirmed